New antibody combo JST-018 enters first human safety trial
NCT ID NCT07595458
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This Phase 1 study is testing whether a single injection of JST-018, a mix of three monoclonal antibodies, is safe and tolerable in 48 healthy adults aged 18 to 55. Participants will be monitored for side effects, drug levels in the blood, and immune responses over one year. This is an early step to see if the drug can be studied further for antiviral use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JST-018 (a combination of 3 monoclonal antibodies)
- What this could lead to
- If safe and well-tolerated, this could pave the way for further studies to see if JST-018 can help fight viral infections.
- What could go wrong
- This is a very early Phase 1 trial in only 48 healthy people, so it cannot yet tell us if the drug works against any disease. Side effects are possible and will be closely monitored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIVIRAL DRUG are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
PPD Las Vegas Clinical Research Unit
RECRUITINGLas Vegas, Nevada, 89113, United States